Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Biogenesis of lysosome-related organelles complex 1 subunit 2 (BLOC1S2) is a protein-coding gene product and a component of the BLOC-1 complex, which is essential for the formation and function of lysosome-related organelles such as melanosomes and platelet dense granules[1][6][8]. BLOC1S2 localizes to the cytosolic face of lysosomes and the centrosome, co-localizing with gamma-tubulin[1][7][8]. It is implicated in vesicle targeting in neurons, neurite extension, and may have a role in cell proliferation[1][8]. Mutations in BLOC1S2 are associated with disorders like Hermansky-Pudlak syndrome, linked to defects in lysosome-related organelle biogenesis[1][6]. There is no evidence that BLOC1S2 is a therapeutic drug target, nor are any interacting drugs or known clinical biomarkers. Its main significance is in cell biology and genetic disease research[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Biogenesis of lysosome-related organelles complex 1 subunit 2 (BLOC1S2).